Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5292]

New drug target discovered for aggressive form of prostate cancer

New drug target discovered for aggressive form of prostate cancer

ESMO 2024: Immunotherapy benefits for early stage gynaecological cancer

ESMO 2024: Immunotherapy benefits for early stage gynaecological cancer

Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer

Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer

WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in patients with ROS1+ non-small cell lung cancer

WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in...

Risk of secondary cancers after CAR T therapy may be similar to risk after other cancer treatments

Risk of secondary cancers after CAR T therapy may be similar to risk after other cancer treatments

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do not respond well to EGFR-TKIs therapy

WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do...

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib analysis of beamion LUNG-1

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib...

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients with HER2-mutant NSCLC

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients...

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients with NSCLC with EGFR PACC mutations

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients...

WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer

WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in...

More from ecancer